RE: Over Reaction - Bounce back Inbound10 Apr 2021 08:42
Key with Novacyt is PRICING POWER plus the huge amount of cash in bank... In comparison to competitors. With such a high 80% EBITDA margin, this give an ability to cut prices quite easily vs new competition. As long as they have the product - which is why all the R&D and new product announcements are key. So what happens if they discount at even 10-20%... As likely will result in more sales that balance out in longer term. This derisks company in my mind. Yes the UK Gov have messed around yet again (no wonder ODX Colin King issues the RNS on the DHSC contract the way he did...). It seems UK Gov is getting a reputation for it!
Under valued. Was undervalued at £7 even without an extension. Even more under valued now. If SP falls further next week I'll be doubling up holdings for sure. Horrible chainsaw cutting RNS but also amazing top up / buy in oppportunity for LTH. £300 MCAP at mo. Lots of talk about the cash in hand but what about overall NET ASSETS. Check half-yr 2020 report and there was alot of INVENTORY too. GOODWILL 2020 amd pre-2020 was £15M alone. Fundamentals will show through in the end. I'm with Porky!!